Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Declines By 8.0%

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 11,430,000 shares, a decrease of 8.0% from the August 15th total of 12,420,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 10.4 days.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in shares of Autolus Therapeutics during the 4th quarter worth approximately $11,793,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after acquiring an additional 2,487,778 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Autolus Therapeutics by 2,603.8% in the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after purchasing an additional 111,131 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Autolus Therapeutics by 74.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after purchasing an additional 1,080,897 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in shares of Autolus Therapeutics during the 4th quarter worth about $768,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Trading Up 0.8 %

Shares of Autolus Therapeutics stock opened at $3.87 on Thursday. Autolus Therapeutics has a 52-week low of $2.01 and a 52-week high of $7.45. The firm has a market capitalization of $1.03 billion, a PE ratio of -3.23 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The company’s fifty day moving average price is $4.10 and its two-hundred day moving average price is $4.42.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect that Autolus Therapeutics will post -0.84 EPS for the current year.

Analyst Upgrades and Downgrades

AUTL has been the topic of several research analyst reports. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.